Evidence map›Paper›PMID 25111166›Full record

ArticleJAMA neurology2014

Effects of the absence of apolipoprotein e on lipoproteins, neurocognitive function, and retinal function.

Angel C Y Mak, Clive R Pullinger, Ling Fung Tang, Jinny S Wong, Rahul C Deo, Jean-Marc Schwarz, Alejandro Gugliucci, Irina Movsesyan, Brian Y Ishida, Catherine Chu and 12 more

Abstract readCase Reports
In one paragraph

Article in JAMA neurology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed
8.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 93 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Multifaceted roles of APOE in Alzheimer disease.Nature reviews. Neurology · 2024
    Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Apolipoprotein E and Atherosclerosis.Current atherosclerosis reports · 2021
    Review
  18. Article
  19. Studies of ApoDCellular and molecular life sciences : CMLS · 2021
    Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors at 6 institutions in 1 country.

Angel C Y MakCardiovascular Research Institute, University of California, San Francisco.
Clive R PullingerCardiovascular Research Institute, University of California, San Francisco.
Ling Fung TangCardiovascular Research Institute, University of California, San Francisco.
Jinny S WongGladstone Institute of Cardiovascular Disease, San Francisco, California.
Rahul C DeoCardiovascular Research Institute, University of California, San Francisco.
Jean-Marc SchwarzCollege of Osteopathic Medicine, Touro University California, Vallejo.
Alejandro GugliucciCollege of Osteopathic Medicine, Touro University California, Vallejo.
Irina MovsesyanCardiovascular Research Institute, University of California, San Francisco.
Brian Y IshidaBoston Heart Diagnostics, Framingham, Massachusetts.
Catherine ChuCardiovascular Research Institute, University of California, San Francisco.
Annie PoonCardiovascular Research Institute, University of California, San Francisco.
Phillip KimDarin M. Camarena Health Centers, Madera, California.
Eveline O StockCardiovascular Research Institute, University of California, San Francisco.
Ernst J SchaeferBoston Heart Diagnostics, Framingham, Massachusetts.
Bela F AsztalosBoston Heart Diagnostics, Framingham, Massachusetts.
Joseph M CastellanoDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California.
Tony Wyss-CorayDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California7Center for Tissue Regeneration, Repair, and Restoration, VA Palo Alto Health Care System, Palo Alto, California.
Jacque L DuncanDepartment of Ophthalmology, University of California, San Francisco.
Bruce L MillerMemory and Aging Center, University of California, San Francisco.
John P KaneCardiovascular Research Institute, University of California, San Francisco.
Pui-Yan KwokCardiovascular Research Institute, University of California, San Francisco.
Mary J MalloyCardiovascular Research Institute, University of California, San Francisco.
University of California, San Francisco · USFramingham Heart Study · USStanford University · USTouro University California · USGladstone Institutes · USUniversity Memory and Aging Center · US

Funding

TDP-43 Loss-of-Function: Biology to BiomarkersP01AG019724 · NIA · UNIVERSITY OF PENNSYLVANIA · PI Jennifer Merrilees · 2002 to 2026
$67.2M
UCSF Dermatology Training GrantT32AR007175 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Wilson Liao, Michael David Rosenblum · 1986 to 2026
$6.1M
NIAMS NIH HHS T32 AR007175NIA NIH HHS P01 AG019724NIA NIH HHS P01AG019724
6 · The paper itself

Abstract

importanceThe identification of a patient with a rare form of severe dysbetalipoproteinemia allowed the study of the consequences of total absence of apolipoprotein E (apoE).

objectivesTo discover the molecular basis of this rare disorder and to determine the effects of complete absence of apoE on neurocognitive and visual function and on lipoprotein metabolism. DESIGN, SETTING, AND

participantsWhole-exome sequencing was performed on the patient's DNA. He underwent detailed neurological and visual function testing and lipoprotein analysis. Lipoprotein analysis was also performed in the Cardiovascular Research Institute, University of California, San Francisco, on blood samples from the proband's mother, wife, 2 daughters, and normolipidemic control participants.

main outcome measuresWhole-exome sequencing, lipoprotein analysis, and neurocognitive function.

resultsThe patient was homozygous for an ablative APOE frameshift mutation (c.291del, p.E97fs). No other mutations likely to contribute to the phenotype were discovered, with the possible exception of two, in ABCC2 (p.I670T) and LIPC (p.G137R). Despite complete absence of apoE, he had normal vision, exhibited normal cognitive, neurological, and retinal function, had normal findings on brain magnetic resonance imaging, and had normal cerebrospinal fluid levels of β-amyloid and tau proteins. He had no significant symptoms of cardiovascular disease except a suggestion of myocardial ischemia on treadmill testing and mild atherosclerosis noted on carotid ultrasonography. He had exceptionally high cholesterol content (760 mg/dL; to convert to millimoles per liter, multiply by 0.0259) and a high cholesterol to triglycerides ratio (1.52) in very low-density lipoproteins with elevated levels of small-diameter high-density lipoproteins, including high levels of prebeta-1 high-density lipoprotein. Intermediate-density lipoproteins, low-density lipoproteins, and very low-density lipoproteins contained elevated apoA-I and apoA-IV levels. The patient's apoC-III and apoC-IV levels were decreased in very low-density lipoproteins. Electron microscopy revealed large lamellar particles having electron-opaque cores attached to electron-lucent zones in intermediate-density and low-density lipoproteins. Low-density lipoprotein particle diameters were distributed bimodally. CONCLUSIONS AND RELEVANCE: Despite a profound effect on lipoprotein metabolism, detailed neurocognitive and retinal studies failed to demonstrate any defects. This suggests that functions of apoE in the brain and eye are not essential or that redundant mechanisms exist whereby its role can be fulfilled. Targeted knockdown of apoE in the central nervous system might be a therapeutic modality in neurodegenerative disorders.

Indexed as

AdultApolipoproteins AApolipoproteins CApolipoproteins EATP-Binding Cassette, Sub-Family C ProteinsCarotid Artery DiseasesExercise TestExomeFrameshift MutationGenotypeHigh-Density Lipoproteins, Pre-betaHumansHyperlipoproteinemia Type IIILipaseLipid MetabolismLipoproteins, HDLABCC2 protein, humanApolipoproteins AApolipoproteins CApolipoproteins EATP-Binding Cassette, Sub-Family C ProteinsHigh-Density Lipoproteins, Pre-betaLipaseLIPC protein, humanLipoproteins, HDLLipoproteins, LDLLipoproteins, VLDLMultidrug Resistance-Associated Protein 2Triglycerides

Identifiers

PMID25111166
PMCPMC4714860
OpenAlexW2118764299

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.